Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment.

ABSTRACT: New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies. Currently, methods to evaluate drug response in organoids are limited because they overlook cellular heterogeneity. In this study, non-invasive optical metabolic imaging (OMI) of cellular heterogeneity was characterized in breast cancer (BC) and pancreatic cancer (PC) patient-derived organoids. Baseline heterogeneity was analyzed for each patient, demonstrating that single-cell techniques, such as OMI, are required to capture the complete picture of heterogeneity present in a sample. Treatment-induced changes in heterogeneity were also analyzed, further demonstrating that these measurements greatly comple

SUBMITTER: Sharick JT 

PROVIDER: S-EPMC7242740 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature